|
1.1 BIOLOGIE - GÉNOME
|
|
|
|
|
Traces of immortality in tumor DNA [DKFZ]
|
|
|
|
|
|
"In the vast majority of the 2,500 cancer cases studied, we observed increased activity of the telomerase gene but without any changes in the genome that could explain this. Epigenetic factors that do not leave any trace in the genome might be partly responsible here."
|
|
|
|
|
|
|
Genomics: data sharing needs an international code of conduct [Nature]
|
|
|
|
|
|
Genomics researchers worldwide are increasingly dealing with vast data sets gathered by consortia spanning many countries. Most are unclear on what to do to protect people’s privacy and to comply with international and national data-protection laws, especially given recent and ongoing changes in legislation.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.4 BIOLOGIE - TECHNOS, MODÈLES
|
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
4.10 DÉP., DIAG. & PRONO. - POUMON
|
|
|
|
4.12 BIOPSIES LIQUIDES
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
5.12 IMMUNOTHÉRAPIES
|
|
|
The Contrarian Who Cures Cancers [Quanta]
|
|
|
|
|
|
Because we have a limited pool of patients, the most promising trials are not accruing sufficient patients fast enough to get these drugs to the clinic as quickly as we can. I think it’s unethical.
|
|
|
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
Merck Charts an R&D-Focused Course Starting With a $6.5B Spinoff [Xconomy]
|
|
|
|
|
|
The spinoff will leave Merck more reliant on its cancer drug portfolio, particularly pembrolizumab (Keytruda). That cancer immunotherapy accounted for $11.1 billion in revenue in 2019, up 55 percent compared to last year. It is by far Merck’s top-selling product, and some analysts on the call questioned whether the company is too dependent on revenue from that drug.
|
|
|
|
|
|
|
|
Spinning Off [In The Pipeline]
|
|
|
|
|
|
It’s worth keeping in mind that this is largely a move for the benefit of Wall Street and the big shareholders. In my experience, it’s not like the folks in the R&D labs usually notice much of a difference when their parent company exits the toothpaste business.
|
|
|
|
|
|
|
|
|
|
5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
|
|
|
Kite isn't flying with investors, and Gilead knows it [Biopharma Dive]
|
|
|
|
|
|
Valuing experimental drugs, particularly ones that originated in another company, is an inexact science, and writedowns like those taken by Gilead this year and last aren't out of the ordinary. But Gilead's future is uncertain, making the diminution of a company bought to secure a leading position in oncology a disappointing admission.
|
|
|
|
|
|
|
5.2.6 PHARMA - BIOTECH
|
|
|
MaaT bags €18M to test microbiome modulators in cancer patients [Fierce Biotech]
|
|
|
|
|
|
A phase 1b that will give solid tumor patients MaaT033 in combination with a checkpoint inhibitor is in the works. The planned trial comes in the wake of evidence that the microbiome influences systemic and anti-tumor immune responses, suggesting drugs that alter the mix of microorganisms in the gut may be able to improve the efficacy of checkpoint inhibitors.
|
|
|
|
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA,...
|
|
|
|
6.1 OBSERVATION
|
|
|
|
6.6 PUBLICATIONS, POLITIQUES SCIENTIFIQUES
|
|
|